Niva Bupa Health Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹2,572 Cr +25.5% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
NB

Niva Bupa Health

Q4 FY26Insurance

Niva Bupa Health Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹2,251Cr
+34.7% YoY
+39.7% QoQ
Net profit
₹159Cr
−22.8% YoY
Turned profitable QoQ
Margin
8%
−7 pp YoY
+14 pp QoQ
Price₹80
Market cap₹14.7K Cr
P/E84.5

The short version

Niva Bupa expects continued strong growth, targeting approximately 25% growth annually over the next 2-3 years. Niva Bupa expects a continued strong growth trajectory with retail health growing around 17%-19% CAGR over the next 5 years.

From Niva Bupa Health's Q4 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Niva Bupa expects continued strong growth, targeting approximately 25% growth annually over the next 2-3 years.
  • Projected Gross Written Premium (GWP) could reach around INR 15,000 - 16,000 crores, up from INR 9,433 crores in FY '26.
  • Growth drivers include:
  • Multichannel distribution expansion, including 58,000 new agents added recently.
  • Diversifying product portfolio to cover nearly all income segments except the poorest.
  • Expansion in Tier 3 and below cities via the Bharat strategy (virtual agency and bank distribution).
  • Increased penetration in digital channels both proprietary and third-party.
  • Industry-wise, retail health insurance is expected to grow at about 17%-19% CAGR over 5 years.

2 more points from Niva Bupa Health's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Niva Bupa Health said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Management emphasizes investment in technology, analytics, and Gen AI as key levers for cost optimization and operational efficiency.
  • Focus on expanding distribution channels, including virtual agency and bank distribution, to drive growth.
  • Solvency ratio remains healthy at 2.49, indicating strong capital position to potentially fund future investments as needed.

Top-ranked in Insurance

Ranked on what management guided this quarter

Guidance-ranked
1Max Financial
Rev 3Mar 2
Rev 3Mar 3
3
Rev 3Mar 3
Sign up free to see 1 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Niva Bupa Health said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Niva Bupa Health said on order book & pipeline — free account, 30 seconds.

Niva Bupa Health — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Niva Bupa Health Q4 FY26 results — key figures

Niva Bupa Health Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue2,2511,671+34.7%1,611+39.7%
Operating profit (EBITDA)182251-27.5%-94—
Operating margin8%15%-7 pp-6%+14 pp
Profit before tax181206-12.1%-88—
Net profit (PAT)159206-22.8%-88—
EPS (₹)0.861.13-23.9%-0.47—

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.6K Cr, net profit ₹136 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Insurance this season

  • Max Financial (Q4 FY26)

    Total APE (Annualized Premium Equivalent) for FY’26: Rs 10,502 crore, up 20% YoY from Rs 8,770 crore in FY’25 (Page 4). Key investor presentation takeaways from

  • Star Health Insu (Q4 FY26)

    Fresh retail business growth driven by both value and volume, with retail policies expanding by 11% YoY in Q4 FY26. Key concall takeaways from Star Health &…

  • Go Digit General (Q4 FY26)

    For fiscal years '25 and '26, retail health business is under 6% of total health segment, indicating room for growth. Key concall takeaways from Go Digit…

  • Medi Assist Healthcare Services (Q4 FY26)

    Core group business organic growth currently tracking at 8%-10% (same-store growth). Key concall takeaways from Medi Assist Healthcare Services's Q4 FY26 earnin

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Niva Bupa Health and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Niva Bupa Health Q4 FY26 results?

Niva Bupa expects continued strong growth, targeting approximately 25% growth annually over the next 2-3 years. Niva Bupa expects a continued strong growth trajectory with retail health growing around 17%-19% CAGR over the next 5 years.

What is Niva Bupa Health share price analysis?

Niva Bupa Health currently shows a neutral. The stock trades at a P/E of 84.5 with a market cap of ₹14,718 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Niva Bupa Health on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.